Corrigendum to “Continuation phase intravenous ketamine in adults with treatment-resistant depression” [J. Affect. Disord. 206 (2016) 300–304](S0165032716313519)(10.1016/j.jad.2016.09.008)

Jennifer L. Vande Voort, Robert J. Morgan, Simon Kung, Keith G. Rasmussen, Jose Rico, Brian A. Palmer, Kathryn M. Schak, Susannah J. Tye, Matthew J. Ritter, Mark A. Frye, William V. Bobo

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

We recently became aware of an error in the classification of one study subject's positive treatment response status at the end of the post-continuation phase of this study. We originally reported that all 5 subjects who achieved depressive symptom remission during the acute phase of the study (and thus received 4 weekly continuation phase ketamine infusions) were classified as responders at the end of the post-continuation phase. However, one of these 5 subjects was misclassified as a positive treatment responder at the end of the post-continuation phase. Therefore, only 4 of these 5 patients were positive treatment responders at the end of the post-continuation phase. Although our main conclusions are not changed, we believe that it is our responsibility to report the error and updated results. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)313
Number of pages1
JournalJournal of Affective Disorders
Volume236
DOIs
StatePublished - Aug 15 2018

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Corrigendum to “Continuation phase intravenous ketamine in adults with treatment-resistant depression” [J. Affect. Disord. 206 (2016) 300–304](S0165032716313519)(10.1016/j.jad.2016.09.008)'. Together they form a unique fingerprint.

Cite this